A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG–AFU trial

P. Blanchard; S. Foulon; G. Louvel; M. Habibian; K. Fizazi

doi:10.1016/j.canrad.2017.06.007

A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG–AFU trial

Titre traduit de la contribution: Rôle de la radiothérapie ablative des métastases chez les patients atteints de cancer de la prostate oligométastatique hormonosensible : un essai du Groupe d’étude des tumeurs urogénitales et de l'Association française d'urologie

P. Blanchard, S. Foulon, G. Louvel, M. Habibian, K. Fizazi

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

9 Citations (Scopus)

Résumé

The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to the primary disease in patients with hormone sensitive oligometastatic prostate cancer.

Titre traduit de la contribution	Rôle de la radiothérapie ablative des métastases chez les patients atteints de cancer de la prostate oligométastatique hormonosensible : un essai du Groupe d’étude des tumeurs urogénitales et de l'Association française d'urologie
langue originale	Anglais
Pages (de - à)	491-494
Nombre de pages	4
journal	Cancer/Radiotherapie
Volume	21
Numéro de publication	6-7
Les DOIs	https://doi.org/10.1016/j.canrad.2017.06.007
état	Publié - 1 oct. 2017

Accès au document

10.1016/j.canrad.2017.06.007

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{87043038b7294c3bbe9361cbcd08eb78,

title = "A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG–AFU trial",

abstract = "The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to the primary disease in patients with hormone sensitive oligometastatic prostate cancer.",

keywords = "Cancer, Metastasis, Prostate, Stereotactic radiotherapy",

author = "P. Blanchard and S. Foulon and G. Louvel and M. Habibian and K. Fizazi",

note = "Publisher Copyright: {\textcopyright} 2017 Soci{\'e}t{\'e} fran{\c c}aise de radioth{\'e}rapie oncologique (SFRO)",

year = "2017",

month = oct,

day = "1",

doi = "10.1016/j.canrad.2017.06.007",

language = "English",

volume = "21",

pages = "491--494",

journal = "Cancer/Radiotherapie",

issn = "1278-3218",

number = "6-7",

}

A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG–AFU trial. / Blanchard, P.; Foulon, S.; Louvel, G. et al.
Dans: Cancer/Radiotherapie, Vol 21, Numéro 6-7, 01.10.2017, p. 491-494.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation

T2 - A GETUG–AFU trial

AU - Blanchard, P.

AU - Foulon, S.

AU - Louvel, G.

AU - Habibian, M.

AU - Fizazi, K.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to the primary disease in patients with hormone sensitive oligometastatic prostate cancer.

AB - The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to the primary disease in patients with hormone sensitive oligometastatic prostate cancer.

KW - Cancer

KW - Metastasis

KW - Prostate

KW - Stereotactic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85028394818&partnerID=8YFLogxK

U2 - 10.1016/j.canrad.2017.06.007

DO - 10.1016/j.canrad.2017.06.007

M3 - Article

C2 - 28869198

AN - SCOPUS:85028394818

SN - 1278-3218

VL - 21

SP - 491

EP - 494

JO - Cancer/Radiotherapie

JF - Cancer/Radiotherapie

IS - 6-7

ER -